Mouse artificial chromosome vector and use thereof

Patent metadata

Field	Value
Publication number	US-12428652-B2
Application number	US-201916981164-A
Country	US
Kind code	B2
Filing date	Mar 15, 2019
Priority date	Mar 16, 2018
Publication date	Sep 30, 2025
Grant date	Sep 30, 2025

Abstract

A mouse artificial chromosome vector is stable in rodent cells, tissues, and/or individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from mouse chromosome 10 and mouse chromosome 16. A cell or a non-human animal may include the vector. The vector may be used for producing proteins and human antibodies.

First claim

The invention claimed is:

1. A mouse artificial chromosome vector, comprising:
a natural centromere derived from a mouse chromosome 10;
a mouse-chromosome-derived long-arm fragment formed by deleting gene Gm8155 and the entire long-arm region of mouse chromosome 10 distal to gene Gm8155 so as to substantially remove endogenous genes in the mouse chromosome;
a telomere sequence so as to form the mouse artificial chromosome vector contained in the deposited cell line DT40 (10MAC) T5-26 (NITE BP-02656),
wherein the vector is stably retained in cells and tissues of a mouse or rat at a retention rate of about 90% or more, and wherein the mouse artificial chromosome vector is capable of transmission to a progeny of the mouse or rat.

2. The vector of claim 1 , further comprising at least one DNA sequence insertion site.

3. The vector of claim 2 , wherein the DNA sequence insertion site selected from the group consisting of a loxP sequence, an FRT sequence, a φC31attB sequence, a φC31attP sequence, a R4attB sequence, a R4attP sequences, a TP901-1attB sequence, a TP901-1attP sequence, a Bxb1attB sequence, and a Bxb1attP sequence.

4. The vector of claim 1 , further comprising:
a reporter gene, a selection marker gene, or a combination thereof.

5. The vector of claim 1 , further comprising:
an exogenous DNA sequence.

6. The vector of claim 5 , wherein the exogenous DNA sequence is a human DNA sequence.

7. The vector of claim 5 , wherein the exogenous DNA sequence is a DNA sequence of a human-chromosome-derived long arm or short arm.

8. The vector of claim 5 , wherein the exogenous DNA sequence is a human immunoglobulin heavy chain gene, a human immunoglobulin light chain gene, or a combination thereof.

9. The vector of claim 5 , wherein the exogenous DNA sequence is a gene or DNA sequence encoding a polypeptide selected from the group consisting of a cytokine, hormone, growth factor, nutritional factor, hematopoietic factor, coagulation factor, hemolysis factor, G protein-coupled receptor, and enzyme, or a gene or DNA sequence used for treatment of a disease selected from the group consisting of a tumor, muscular dystrophy, hemophilia, neurodegenerative disease, autoimmune disease, allergic disease, and genetic disease or a gene or DNA sequence encoding a T-cell receptor or a human leukocyte antigen.

10. An isolated mouse or rat cell comprising the mouse artificial chromosome vector of claim 1 .

11. The cell of claim 10 , wherein the cell is selected from the group consisting of somatic cell, stem cell, and precursor cell.

12. A method for producing a protein, the method comprising: culturing the isolated cell of claim 10 comprising the mouse artificial chromosome vector comprising an exogenous DNA sequence to produce a protein encoded by the exogenous DNA; and collecting the protein produced that is encoded by the DNA.

Assignees

• Nat Univ Corp Tottori Univ
• Trans Chromosomics Inc

Inventors

• Kazuki Yasuhiro
• Oshimura Mitsuo
• Abe Satoshi

Classifications

• A01K2217/072

  maintaining or altering function, i.e. knock in · CPC title

• A01K2207/15

  Humanized animals · CPC title

• A01K67/0278

  Knock-in vertebrates, e.g. humanised vertebrates · CPC title

• C12N2015/8518

  expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title